immunotherapy

Background and PurposeInvestigating the assessment of innovative serum indicators with elevated sensitivity and specificity is crucial for enhancing the early diagnosis and prognosis of HCC (Hepatocellular carcinoma). This study aimed to evaluate the efficacy of COPA (Coatomer Subunit Alpha) in diagnosing hepatocellular carcinoma and assessing the effectiveness of immunotherapy.MethodsThis study …

Mount Sinai study shows tumors significantly reduced in patients who received dual approach before surgery

Stand Up To Cancer(r) (SU2C) today announced the recipients of the SU2C Nina Nicolai Pancreatic Cancer Innovation in Collaboration Award.

Bladder cancer begins in the lining of the bladder, the organ that stores urine before it leaves the body. Some bladder cancers grow slowly, while others are much more aggressive and are more likely to come back after treatment. One of the standard treatments for high-risk bladder cancer that has not spread into the bladder […] The post New Immunotherapy Helps Many Bladder Cancer Patients Avoid S…

Nature Communications, Published online: 04 August 2026; doi:10.1038/s41467-026-76331-8 Acute lung injury (ALI) involves promotion of inflammatory pathways and macrophage pyroptosis. Here the authors propose a macrophage targeting potassium containing catalytic particle which reduces ALI through scavenging reactive oxygen species, downregulation of gasdermin D and inhibition of macrophage pyropto…

Muscle-invasive bladder cancer remains a significant clinical challenge, due in part to the highly aggressive nature of the disease.  This malignancy | Cancer

BackgroundCurrently, immune checkpoint inhibitors (ICIs) have become a mainstay in treating advanced esophageal cancer (EC), yet the predictive significance of routinely collected clinicopathological characteristics for overall survival (OS) remains uncertain.MethodsWe searched EMBASE, MEDLINE, Cochrane Library, Web of Science, and ClinicalTrials.gov for phase III randomized controlled trials (RC…

The standard first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma (R/M-NPC) is currently a combination of a programmed cell death protein-1 (PD-1) blockade and gemcitabine-cisplatin. However, effective options beyond second-line settings are limited, and a recommended regimen is currently unavailable. This report presents a case study highlighting the significan…

Conventional TIL therapy, clinically validatedrecently with the U.S. Food and Drug Administration approval of lifileucel for advanced melanoma,stillfaces substantial hurdles.

The advent of immune checkpoint inhibitors (ICIs) has marked a paradigm shift in cancer treatment, yet a significant portion of breast cancer patients fail to respond to these therapies.

Nature Communications, Published online: 17 June 2026; doi:10.1038/s41467-026-74570-3 Therapeutic options for patients with treatment-refractory metastatic urothelial carcinoma (mUC) are much needed. Here, the authors report the outcomes and translational analysis of the phase I/II ICRA trial evaluating whether paclitaxel plus tremelimumab (anti-CTLA-4) with or without durvalumab (anti-PD-L1) ind…

This tip sheet from Sylvester Comprehensive Cancer Center, at the University of Miami Miller School of Medicine, features several cancer-related story ideas including paradoxical mesothelioma findings, a new immunotherapy drug for relapsed multiple myeloma, how gliomas evolve after treatment and more.

The Alliance for Clinical Trials in Oncology (Alliance) today announced that the U.S. Food and Drug Administration has accepted for review Genentech's supplemental Biologic License Application for their immunotherapy drug atezolizumab (Tecentriq®) for the treatment of patients with stage III colon cancer with deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR).

Modern cancer treatment has entered a new era thanks to immunotherapy. Instead of directly attacking cancer cells with chemicals or radiation, immunotherapy encourages the immune system to do the job itself. This approach has helped many patients live longer and has changed the outlook for several types of cancer. One of the most widely used […] The post Scientists Find a Smarter Way to Track Can…

A team led by researchers from the National Center for Tumor Diseases (NCT/UCC) Dresden at the Carl Gustav Carus University Hospital (UKD) and the Carl Gustav Carus Faculty of Medicine at the TUD Dresden University of Technology will present clinical results for the first time on May 31, 2026, at this year’s annual meeting of the American Society of Clinical Oncology (ASCO) regarding a new cancer…

Nature Communications, Published online: 25 May 2026; doi:10.1038/s41467-026-73562-7 While first-line immunochemotherapy has shown efficacy in patients with extensive-stage small-cell lung cancer (ES-SCLC), survival benefit is limited. Here, the authors report a phase II randomised clinical trial comparing durvalumab (anti-PD-1) plus anlotinib (multi-TKI) against durvalumab alone as maintenance t…

A drug that millions of people already use for asthma and allergies may one day become part of cancer treatment, according to a new study from Northwestern Medicine. Researchers discovered that medications blocking a molecule called CysLTR1 may help the immune system fight aggressive cancers that often resist modern immunotherapy treatments. The findings were published […] The post Asthma drug co…

Researchers at Moffitt Cancer Center report encouraging early results from a phase 2 study examining whether immunotherapy can improve results when added to radiotherapy-based treatment regimen for men with aggressive prostate cancer. The work, led by Kosj Yamoah, MD, Ph.D., chair of the Radiation Oncology Department at Moffitt, was published in the Journal for ImmunoTherapy of Cancer.

Nature Communications, Published online: 08 May 2026; doi:10.1038/s41467-026-72242-w CheckMate 650 was a multicohort phase 2 trial designed to study the safety and clinical activity of nivolumab plus ipilimumab combination therapy in patients with metastatic castration-resistant prostate cancer. Here the authors report the results of the randomized portion of the trial, including three different …

Researchers at the Icahn School of Medicine at Mount Sinai and the Mount Sinai Tisch Cancer Center have identified a promising new strategy to overcome resistance to immunotherapy in colorectal cancer, one of the leading causes of cancer-related deaths worldwide.